10:46 AM EDT, 08/07/2025 (MT Newswires) -- Genmab ( GMAB ) said Thursday that subcutaneous epcoritamab in combination with rituximab and lenalidomide showed a statistically significant improvement in patient response and delayed disease progression in a phase 3 lymphoma clinical study.

The study, which compared the triple drug combination with rituximab and lenalidomide alone in adult patients with relapsed or refractory follicular lymphoma, met the dual primary endpoints, according to the company.

Genmab ( GMAB ) said the US Food and Drug Administration accepted its supplemental biologics license application for subcutaneous epcoritamab under priority review last month with a decision expected by Nov. 30.

Shares of the company were up 5.3% in recent trading.

Price: 22.65, Change: +1.14, Percent Change: +5.30